Glaukos Co. (NYSE:GKOS) CFO Sells $137,940.88 in Stock

Glaukos Co. (NYSE:GKOS - Get Free Report) CFO Alex R. Thurman sold 1,372 shares of the firm's stock in a transaction on Monday, April 8th. The shares were sold at an average price of $100.54, for a total transaction of $137,940.88. Following the completion of the transaction, the chief financial officer now directly owns 52,532 shares of the company's stock, valued at $5,281,567.28. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Glaukos Trading Up 0.6 %

Shares of GKOS traded up $0.56 during trading hours on Tuesday, reaching $101.19. 394,893 shares of the company traded hands, compared to its average volume of 706,070. The firm has a market cap of $5.01 billion, a price-to-earnings ratio of -36.40 and a beta of 1.08. Glaukos Co. has a 12-month low of $45.38 and a 12-month high of $102.33. The company has a current ratio of 5.34, a quick ratio of 4.78 and a debt-to-equity ratio of 0.77. The stock's fifty day moving average price is $91.17 and its 200 day moving average price is $79.56.

Glaukos (NYSE:GKOS - Get Free Report) last released its quarterly earnings data on Wednesday, February 21st. The medical instruments supplier reported ($0.63) earnings per share for the quarter, missing the consensus estimate of ($0.56) by ($0.07). The firm had revenue of $82.40 million during the quarter, compared to the consensus estimate of $81.00 million. Glaukos had a negative net margin of 42.79% and a negative return on equity of 22.67%. The business's revenue was up 15.7% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($0.53) earnings per share. Sell-side analysts forecast that Glaukos Co. will post -2.18 earnings per share for the current year.

Analyst Ratings Changes

Several research analysts have commented on GKOS shares. Stifel Nicolaus reaffirmed a "buy" rating and set a $110.00 price objective on shares of Glaukos in a research note on Wednesday, April 3rd. Wells Fargo & Company lifted their price objective on shares of Glaukos from $83.00 to $103.00 and gave the stock an "overweight" rating in a research note on Thursday, February 22nd. JPMorgan Chase & Co. raised shares of Glaukos from a "neutral" rating to an "overweight" rating and lifted their price objective for the stock from $66.00 to $91.00 in a research note on Thursday, December 21st. Truist Financial reaffirmed a "buy" rating and set a $110.00 price objective on shares of Glaukos in a research note on Monday. Finally, Needham & Company LLC lifted their price objective on shares of Glaukos from $105.00 to $108.00 and gave the stock a "buy" rating in a research note on Thursday, February 22nd. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and seven have given a buy rating to the company. According to MarketBeat, Glaukos currently has a consensus rating of "Moderate Buy" and a consensus price target of $98.30.

Institutional Trading of Glaukos

Several institutional investors and hedge funds have recently made changes to their positions in the company. Vanguard Group Inc. raised its holdings in shares of Glaukos by 0.4% in the third quarter. Vanguard Group Inc. now owns 5,380,720 shares of the medical instruments supplier's stock valued at $286,470,000 after acquiring an additional 23,473 shares in the last quarter. Brown Capital Management LLC raised its holdings in Glaukos by 3.4% in the fourth quarter. Brown Capital Management LLC now owns 2,697,794 shares of the medical instruments supplier's stock worth $214,448,000 after purchasing an additional 89,420 shares in the last quarter. Braidwell LP raised its holdings in Glaukos by 8.7% in the first quarter. Braidwell LP now owns 1,806,651 shares of the medical instruments supplier's stock worth $90,513,000 after purchasing an additional 144,800 shares in the last quarter. State Street Corp raised its holdings in Glaukos by 1.8% in the second quarter. State Street Corp now owns 1,782,347 shares of the medical instruments supplier's stock worth $126,921,000 after purchasing an additional 31,471 shares in the last quarter. Finally, Fred Alger Management LLC raised its holdings in Glaukos by 9.2% in the third quarter. Fred Alger Management LLC now owns 1,780,690 shares of the medical instruments supplier's stock worth $133,997,000 after purchasing an additional 150,102 shares in the last quarter. 99.04% of the stock is currently owned by institutional investors.

About Glaukos

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.